Edition:
United Kingdom

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

2.88USD
8:59pm GMT
Change (% chg)

$-0.15 (-4.95%)
Prev Close
$3.03
Open
$3.00
Day's High
$3.01
Day's Low
$2.88
Volume
3,268
Avg. Vol
9,819
52-wk High
$5.25
52-wk Low
$2.40

Chart for

About

AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.... (more)

Overall

Beta: --
Market Cap(Mil.): $40.32
Shares Outstanding(Mil.): 11.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Azurrx Biopharma Enrolls New Patients For Phase IIA Study Of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES ENROLLMENT OF THREE NEW PATIENTS FOR ITS PHASE IIA STUDY OF MS1819-SD Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD

* AZURRX BIOPHARMA ANNOUNCES RECEIPT OF REQUIRED APPROVALS TO ADD FRENCH CLINICAL SITE FOR ITS PHASE IIA STUDY OF MS1819-SD FOR EXOCRINE PANCREATIC INSUFFICIENCY

18 Jan 2018

BRIEF-AzurRx Biopharma receives $2 mln in proceeds from exercise of warrants

* AZURRX BIOPHARMA RECEIVES $2 MILLION IN PROCEEDS FROM EXERCISE OF WARRANTS

17 Jan 2018

BRIEF-AzurRx Biopharma files for mixed shelf offering of up to $10 mln

* AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​ Source text: [http://bit.ly/2z4AEuv] Further company coverage:

01 Nov 2017

BRIEF-Azurrx Biopharma, Mayoly Spindler announce IMPD submission

* Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission

20 Oct 2017

BRIEF-AzurRx BioPharma files for stock shelf of upto $10 mln

* Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing‍​‍​ Source text for Eikon: (http://bit.ly/2hChpOb) Further company coverage:

11 Oct 2017

BRIEF-AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency

* AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi)

27 Sep 2017

BRIEF-Azurrx announces appointment of Chief Financial Officer

* Azurrx announces appointment of Maged Shenouda as Chief Financial Officer Source text for Eikon: Further company coverage:

25 Sep 2017

BRIEF-Azurrx reaches 6th patient enrollment of midstage trial for pancreas drug

* Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis

23 Aug 2017

Earnings vs. Estimates